# GLP-1s After a Kidney Transplant

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/glp1-after-a-kidney-transplant

> A meta-analysis of 54,680 transplant recipients reports mortality nearly halved and kidney function improving. Four studies stand behind the mortality figure, and the size of the benefit is the reason to be careful with it.

## Key points

- 17 studies, 54,680 kidney transplant recipients.
- Mortality HR 0.53, but from just 4 studies, all observational.
- The believable results are the boring ones: eGFR +2 units, HbA1c −0.54%.
- Drugs rarely halve mortality; confounding by indication routinely produces results like that.

Metabolic complications after a kidney transplant drive how long the graft and the patient last. A 2026 meta-analysis pooled 17 studies covering **54,680 transplant recipients** and reported results that look almost too good: mortality nearly halved, cardiovascular events nearly halved, kidney function improving rather than declining.[1] The size of those numbers is the reason to be careful with them.

## What was reported

*Pooled outcomes in kidney transplant recipients using GLP-1 drugs. The Studies column gives the number of studies behind each figure.*

| Outcome | Pooled result | Studies |
| --- | --- | --- |
| All-cause mortality | HR 0.53 (95% CI 0.36–0.79) | 4 |
| Major adverse cardiovascular events | OR 0.55 (95% CI 0.47–0.66) | 3 |
| eGFR at 6 months | +1.99 mL/min/1.73m² (0.52–3.47) | 5 |
| eGFR at 12 months | +2.24 mL/min/1.73m² (0.02–4.46) | 6 |
| HbA1c | −0.54% (95% CI −0.89 to −0.19) | 13 |

Kidney function was stable at three months, improved at six and twelve, and was preserved at twenty-four.[1] For a transplanted kidney, not declining is itself the goal.

## Why a 47% mortality reduction should make you cautious

Drugs rarely halve mortality. Confounding by indication routinely produces results that look like that, and this evidence is entirely observational.

Consider who receives a GLP-1 after a transplant. It is the recipient doing well enough that a nephrologist turns attention to long-term metabolic risk, not the one with an unstable graft, active infection, or poor functional status. Those patients would have lower mortality than the comparison group whatever they were prescribed. A hazard ratio of 0.53 is the kind of result that selection produces.

> The mortality figure rests on four studies and the cardiovascular figure on three, so read the Studies column before the confidence interval.

The HbA1c and eGFR results are more believable because they are less impressive. A 0.54 point reduction in HbA1c, pooled from thirteen studies, is in line with what these drugs produce. An eGFR gain of about two units, from five and six studies, is small, consistent, and measures something that resists wishful reporting. Whether weight loss alone can flatter an eGFR is a fair question, and [one trial tested it against directly measured filtration](https://glpwatchdog.org/research/does-weight-loss-fake-kidney-numbers).

## What makes this population different

- **Immunosuppression is narrow-therapeutic-index prescribing.** Tacrolimus levels are monitored closely for good reason, and anything that changes absorption is a live concern, which is why this belongs with the transplant team rather than a telehealth intake. Our [interactions article](https://glpwatchdog.org/research/glp1-and-your-other-medications) covers the general mechanism.
- **Post-transplant diabetes is common** and partly caused by the immunosuppression itself, so metabolic treatment is not optional add-on care here.
- **The graft is the outcome.** Weight is a means to it rather than the point, which changes how a benefit-risk conversation runs.
- **Dehydration matters more.** Gastrointestinal effects that are unpleasant in the general population are a graft-function concern in someone with a single functioning kidney.

> **Nothing here is a reason to seek a GLP-1 from a telehealth seller after a transplant.** This is prescribing that needs to sit alongside immunosuppression monitoring, and a platform that has never seen your tacrolimus levels cannot do it. If a seller’s intake does not ask about transplant history, that tells you something about the intake.

## Where this leaves a patient

A patient here is in an unusually good position, with an unusually weak evidence base. The direction of every measured outcome is favorable, the mechanism is plausible, and the population has a great deal to gain. What is missing is a randomized trial. Until there is one, the drugs look useful here and the size of the reported benefit is probably not real.

That is a reasonable basis for a conversation with a transplant nephrologist, and not a basis for confidence about how much benefit to expect.

## Frequently asked questions

### Can kidney transplant recipients take GLP-1 drugs?

They do, and a 2026 meta-analysis of 17 studies in 54,680 recipients found favorable results across mortality, cardiovascular events, HbA1c and kidney function. All of it is observational, so it belongs in a conversation with the transplant team rather than being treated as established.

### Do they cut mortality by half?

Almost certainly not. The pooled hazard ratio was 0.53, but it rests on four studies and the evidence is observational. Nephrologists prescribe these drugs to recipients who are doing well enough to be thinking about long-term metabolic risk, and that selection alone can produce a result of this size.

### What about kidney function itself?

This is the more trustworthy part. eGFR was stable at three months, improved by about 2 mL/min/1.73m² at six and twelve months, and was preserved at twenty-four. The changes are small and consistent, and for a transplanted kidney, not declining is the goal.

### Is there an interaction with anti-rejection medication?

It is the right question to ask your transplant team. Immunosuppressants such as tacrolimus are monitored closely because the therapeutic window is narrow, and any drug that alters absorption warrants attention. In the 2026 meta-analysis, tacrolimus levels were unaffected at six months and modestly lower at one year, without harm to graft function. This is a reason for the prescribing to sit with the transplant service.

### Could I get one from a telehealth seller?

You should not want to. This prescribing needs to sit alongside immunosuppression monitoring, and a platform that has never seen your levels cannot do that. An intake that does not even ask about transplant history is telling you something about the intake.

## References

1. Kanbay M, Abdel-Rahman SM, Guldan M, et al. Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis. Clinical Kidney Journal. 2026. PMID: 42017027. https://pubmed.ncbi.nlm.nih.gov/42017027/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1s After a Kidney Transplant", published 2026-08-19, updated 2026-11-01. https://glpwatchdog.org/research/glp1-after-a-kidney-transplant

Canonical HTML page: https://glpwatchdog.org/research/glp1-after-a-kidney-transplant

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
